Skip to main content

Histone H1.0—a potential molecular marker with prognostic value for patients with malignant gliomas



Histones are proteins closely associated with the DNA molecules and serve as a structural scaffold for the organization of chromatin. They play an important role in the regulation of gene expression by changing the level of DNA compaction.

The special subtype of the linker histone family—H1 zero (H1.0) is generally expressed in non-dividing, terminally differentiated cells.

The aim of our study is to investigate the correlation between the quantities of histone H1.0 in human gliomas, the histopathological grade and the overall survival.

Material and method

Twenty-nine (N = 29) patients with intraaxial lesions underwent a microsurgical tumor resection. Tumor samples were snap-frozen in liquid nitrogen immediately after resection.

Following a specific protocol, linker histones were extracted from the tumor specimens and the quantities of histone H1.0 were assessed. All patients were followed up prospectively.


Of the 29 patients in our study (M:F = 17:12), five had a grade II astrocytoma, seven had a grade III, and 17 had a grade IV, according to the World Health Organization (WHO) classification.

At the end of the study, three patients were still alive.

The mean quantities of H1.0 were: 23.3 for grade II tumors, 13.9 for grade III and 11.3 for grade IV tumors.

The statistical analysis demonstrated that the histological grade, age and Karnofsky performance status (KPS) remain among the most reliable predictive factors for the survival of patients with gliomas.

Grade III–IV gliomas had significantly less histone H1.0 than grade II gliomas. Conformably, in a multivariate Cox regression analysis, H1.0 made a small but significant contribution (p < 0.05) to survival rates.


Our study confirmed that histone H1.0 is a potential biological marker with prognostic value for the survival of patients with gliomas. The quantities of histone H1.0 are correlated to the histopathological grade of the tumor. The more aggressive and malignant gliomas tend to have lower quantities of histone H1.0.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol 10:1057–68

    Article  Google Scholar 

  2. Van Holde KE (1989) Chromatin. Springer, New York

    Book  Google Scholar 

  3. Luger K (2006) Dynamic nucleosomes. Chromos Res 14:5–16

    Google Scholar 

  4. Fischle W, Wang Y, Allis D (2003) Histone and chromatin cross-talk. Curr Opinion Cell Biol 15:172–183

    PubMed  Article  CAS  Google Scholar 

  5. Harvey AC, Downs JA (2004) What functions do linker histones provide? Mol Microbiol 53(3):771–775

    PubMed  Article  CAS  Google Scholar 

  6. McBryant S, Lu X, Hansen J (2010) Multifunctionality of the linker histones: an emerging role for protein-protein interactions. Cell Res 20:519–528

    PubMed  Article  CAS  Google Scholar 

  7. Sancho M, Diani E, Beato M, Jordan A (2008) Depletion of human histone H1 variants uncovers specific roles in gene expression and cell growth. PlosGenet 4:e1000227

    Google Scholar 

  8. Warneboldt J, Haller F, Horstmann O, Danner B, Füzesi L, Doenecke D, Happel N (2008) Histone H1x is highly expressed in human neuroendocrine cells and tumours. BMC Cancer 8:388

    PubMed  Article  Google Scholar 

  9. Zlatanova J, Doenecke D (1994) Histone H1 zero: A major player in cell differentiation? FASEB J 8:1260–1268

    PubMed  CAS  Google Scholar 

  10. Marks D, Kanefsky T, Keller B, Marks A (1975) The presence of histone H1 degree in human tissues. Canc Res 35:886–889

    CAS  Google Scholar 

  11. Tsanev R, Hadjiolov D (1978) Chromosomal proteins in hepatocarcinogenesis. J Cancer Res Clin Oncol 91:237–247

    Google Scholar 

  12. Giancotti V, Bandiera A, Ciani L, Santoro D, Crane-Robinson C, Goodwin GH, Boiocchi M, Dolcetti R, Casetta B (1993) High-mobility-group (HMG) proteins and histone H1 subtypes expression in normal and tumor tissues of mouse. Eur J Biochem 213:825–832

    PubMed  Article  CAS  Google Scholar 

  13. Kostova N, Srebreva L, Milev A, Bogdanova O, Rundquist I, Lindner H, Markov D (2005) Immunohistochemical demonstration of histone H1(0) in human breast carcinoma. Histochem Cell Biol 124:435–443

    PubMed  Article  CAS  Google Scholar 

  14. Smith BJ, Johns EW (1980) Isolation and characterisation of subfractions of nuclear protein H1 degree. FEBS Lett 110(1):25–29

    PubMed  Article  CAS  Google Scholar 

  15. Kolev N, Georgieva M, Gabrovsky N, Uzunov K, Miloshev G (2006) Assessment of histone H10 levels in Glioblastoma multiforme. Compt Rendus de l'Acad Bulgare des Sci 59:89–98

    Google Scholar 

  16. Albig W, Runge D, Kratzmeier M, Doenecke D (1998) Heterologous expression of human H1histones in yeast. FEBS Lett 435:245–250, differentiation? The FASEB J 8:1260–1268

    PubMed  Article  CAS  Google Scholar 

  17. Miloshev G, Zlatanova J, Srebreva L, Tsanev R (1985) Presence of a H1о-type histone in an invertebrate—the bivalve mollusk Anodonta cygnea. Comp Biochem Physiol 82B:759–761

    CAS  Google Scholar 

  18. Lea M (1987) Relationship of H1(0) histone to differentiation and cancer. Cancer Biochem Biophys 3:199–209

    Google Scholar 

  19. Gunjan A, Alexander B, Sittman D, Brown DT (1999) Effects of H1 histone variant overexpression on chromatin structure. J Biol Chem 274:37950–37956

    PubMed  Article  CAS  Google Scholar 

  20. Girardot V, Rabilloud T, Yoshida Y, Beppu T, Lawrence J, Khochbin S (1994) Relationship between core histone acetylation and histone H10 gene activity. Eur J Biochem 224:885–892

    PubMed  Article  CAS  Google Scholar 

  21. Mannironi C, Rossi V, Biondi A, Ubezio P, Masea G, Barbui T, D’Incalci M (1987) Histone H1° is synthesized by human lymphocytic leukemia cells but not by normal lymphocytes. Blood 70:1203–1207

    Google Scholar 

Download references


N.G. is supported by the Bulgarian Science Fund, Grant number ТК02-468/2009.

M.G. is supported by the Bulgarian Science Fund, Grant number DMU 02/8 and from the World Federation of Scientists, National Scholarship Programme.

G. M. is supported by the Bulgarian Science Fund, Grant number DID 02/35.

Conflicts of interest


Author information

Authors and Affiliations


Corresponding author

Correspondence to Nikolay Gabrovsky.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gabrovsky, N., Georgieva, M., Laleva, M. et al. Histone H1.0—a potential molecular marker with prognostic value for patients with malignant gliomas. Acta Neurochir 155, 1437–1442 (2013).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Glioma
  • Histone
  • Epigenetics
  • Prognostic factors